There are 3 messages in this issue.
Topics in this digest:
1. MEDICAL: DISEASES: CANCER: LEUKEMIA: Arsenic Compound Improves
From: David P. Dillard
2. BUSINESS: COMPANY: INFORMATION: FOREIGN : COUNTRIES: GREAT BRITAIN:
From: David P. Dillard
3. WEB SITE DESIGN AND PROMOTION: USABILITY: Research Based Web Design
From: David P. Dillard
Messages
________________________________________________________________________
1. MEDICAL: DISEASES: CANCER: LEUKEMIA: Arsenic Compound Improves
Posted by: "David P. Dillard" [EMAIL PROTECTED] jwneastro
Date: Wed Jan 24, 2007 2:18 pm ((PST))
MEDICAL: DISEASES: CANCER: LEUKEMIA:
Arsenic Compound Improves Survival of Adults with Uncommon Form of
Leukemia
Date: Wed, 24 Jan 2007 16:04:11 -0500
From: "NIH OLIB (NIH/OD)" <[EMAIL PROTECTED]>
To: [EMAIL PROTECTED]
Subject: Arsenic Compound Improves Survival of Adults with Uncommon Form
of Leukemia
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH
NIH News
National Cancer Institute (NCI)
<http://www.cancer.gov/>
EMBARGOED FOR RELEASE: Wednesday, January 24, 2007 4:00 p.m. EST
CONTACT: NCI Media Relations Branch, 301-496-6641,
<e-mail: [EMAIL PROTECTED]>
CALGB Press Office, (773) 702 6241, <email: [EMAIL PROTECTED]>
ARSENIC COMPOUND IMPROVES SURVIVAL OF ADULTS WITH UNCOMMON FORM OF
LEUKEMIA
Positive results of a phase III cancer clinical trial in an uncommon form
of leukemia were released today. The results showed that adult patients
with previously untreated acute promyelocytic leukemia (APL) who had
standard chemotherapy to induce remission of their disease, and then
received the chemotherapy drug arsenic trioxide to maintain remission, had
a significantly better event-free survival (more patients free of
leukemia) and better overall survival than those who received only
standard chemotherapy. The trial was sponsored by the National Cancer
Institute (NCI), part of the National Institutes of Health, and was led by
one of its Cooperative Clinical Trials Groups -- the Cancer and Leukemia
Group B (CALGB).
"The positive result in a clinical trial of a common element holding an
uncommon disease in remission for a significant period of time is very
encouraging," said NIH Director Elias A. Zerhouni, M.D.
Acute promyelocytic leukemia, an uncommon subtype of acute myeloid
leukemia (AML), accounts for approximately 10 percent of AML cases, or
about 1,500 cases per year, in the United States. It is most often
diagnosed in young and middle aged adults, but it also occurs in children
and older adults. Standard chemotherapy regimens produce complete
remission rates of approximately 70 percent and show a five-year survival
without the recurrence of disease in 35 to 45 percent of patients.
"Achieving success in a clinical trial for a rare cancer is a difficult
task due to the limited number of patients eligible to enroll in the
trial, so this is very encouraging news for all patients with this form of
leukemia," said NCI Director John Niederhuber, M.D. "This positive
outcome demonstrates, yet again, the benefits of clinical trials and will
hopefully serve as encouragement for others to join such trials."
This particular type of leukemia is often accompanied by life-threatening
bleeding at diagnosis that typically worsens, even as initial treatment is
administered. Treatment has improved dramatically in recent years with
the addition of all-trans retinoic acid (ATRA, or tretinoin) to
chemotherapy. More recently, arsenic trioxide (Trisenox [R]) was shown to
be an effective drug for producing a second remission in patients who had
a relapse or recurrence of their APL after initial treatment. Both ATRA
and arsenic trioxide are approved by the U.S. Food and Drug Administration
for the treatment of APL.
The CALGB-coordinated study tested the effectiveness and side effects from
adding two 25-day courses of intravenous arsenic trioxide to the
combination of ATRA and chemotherapy. Patients with newly diagnosed APL
were randomly assigned to receive either (1) the standard remission
treatment with ATRA twice daily, daunorubicin for four days, and
cytarabine for seven days, both of which are standard chemotherapy drugs
for this disease, followed by a standard post-remission regimen with two
more courses of ATRA plus daunorubicin, or (2) the experimental treatment
where patients received the same standard treatment with the addition of
two courses of arsenic trioxide given immediately after the patient
entered a complete or partial remission and before the standard
post-remission regimen. The arsenic trioxide course was a two hour
intravenous infusion, Monday through Friday, on an outpatient schedule for
five weeks. Patients who remained free of visible leukemia after
completion of the remission therapy then received an additional year of
treatment with oral chemotherapy drugs to prevent the leukemia from relapsing.
Between June, 1999 and March, 2005, 582 patients enrolled on this study.
Patients participated through one of five NCI-sponsored North American
Cooperative Oncology Groups, including CALGB, Eastern Cooperative Oncology
Group (ECOG), Southwest Oncology Group (SWOG), Children's Oncology Group
(COG) and the National Cancer Institute of Canada, Clinical Trials Group
(NCIC-CTG). By study design, patients less than 15 years of age (11
percent of the entire group) were not assigned to the treatment that
contained arsenic trioxide.
The percentage of adult patients who remained alive and in remission --
free of relapse of their leukemia -- three years after diagnosis was 77
percent on the treatment arm that included arsenic trioxide compared to 59
percent on the standard treatment arm. This difference was highly
statistically significant. The greater effectiveness of the experimental
combination also resulted in better overall survival after three years of
86 percent for the patients who received the arsenic trioxide compared to
77 percent for patients on the standard treatment arm.
Patients were followed for a median period of 29 months. After reviewing
the study results, a data safety monitoring board notified the
investigators and the NCI of the positive results, and the findings are
being released so that all APL patients will have a chance to benefit from
this therapy.
Bayard Powell, M.D., Wake Forest University, Winston-Salem, N.C.,
principal investigator of the study, said, "The willingness of patients
with leukemia and their physicians to participate in this important
clinical trial has markedly improved the outcome for these and future
patients with APL."
The side effects from treatment were reported at the annual meeting of the
American Society of Hematology in Orlando, Fla., in December 2006. There
was no difference in hematologic (blood count) toxicities between the
group who received arsenic and those who did not, but there was a slightly
higher incidence of headache and infection in the group who received
arsenic trioxide. A complete scientific presentation of these study
results is planned for the annual meeting of the American Society of
Clinical Oncology in Chicago, Ill., in June 2007.
Richard Larson, M.D., University of Chicago, Ill., a co-investigator of
the study, noted, "These results indicate that arsenic trioxide should be
considered as part of the initial treatment of patients with acute
promyelocytic leukemia."
The study was sponsored by the Division of Cancer Treatment and Diagnosis
(DCTD), NCI, under a Clinical Trials Agreement between DCTD, NCI and
Cephalon, Inc., Frazer, Pa. (marketers and sellers of Trisenox [R]) and
monitored by an independent Data and Safety Monitoring Board that
recommended release of the results.
For more information about cancer, please visit the NCI Web site at
<http://www.cancer.gov>
or call NCI's Cancer Information Service at
1-800-4-CANCER (1-800-422-6237).
The National Institutes of Health (NIH) -- The Nation's Medical Research
Agency -- includes 27 Institutes and Centers and is a component of the
U.S. Department of Health and Human Services. It is the primary federal
agency for conducting and supporting basic, clinical and translational
medical research, and it investigates the causes, treatments, and cures
for both common and rare diseases. For more information about NIH and its
programs, visit
<http://www.nih.gov>
###
This NIH News Release is available online at:
<http://www.nih.gov/news/pr/jan2007/nci-24.htm>.
Sincerely,
David Dillard
Temple University
(215) 204 - 4584
[EMAIL PROTECTED]
Net-Gold
<http://groups.yahoo.com/group/net-gold>
<http://listserv.temple.edu/archives/net-gold.html>
General Internet & Print Resources
<http://library.temple.edu/articles/subject_guides/general.jsp>
<http://www.learningis4everyone.org/>
<http://www.edu-cyberpg.com/ringleaders/davidd.html>
Digital Divide Network
<http://www.digitaldivide.net/profile/jwne>
Educator-Gold
<http://groups.yahoo.com/group/Educator-Gold/>
Messages in this topic (1)
________________________________________________________________________
________________________________________________________________________
2. BUSINESS: COMPANY: INFORMATION: FOREIGN : COUNTRIES: GREAT BRITAIN:
Posted by: "David P. Dillard" [EMAIL PROTECTED] jwneastro
Date: Thu Jan 25, 2007 3:00 am ((PST))
BUSINESS: COMPANY: INFORMATION:
FOREIGN : COUNTRIES: GREAT BRITAIN:
Companies House Website
Companies House Website
<http://www.companies-house.gov.uk/>
"The foundation of company information exchange in the UK: helping
business, informing the public and benefiting the economy."
About Us
<http://www.companies-house.gov.uk/about/functionsHistory.shtml>
Main Functions and History
Companies House Board and Management
The Board of Directors
Meeting Minutes
The Steering Board
Meeting Minutes
Events
Seminars
Exhibitions
Seminars for Newly Appointed Directors & Secretaries
Focus Groups
WebFiling Seminars
Library
Corporate Documents
Policy Documents
Guidance
Forms Online
Register Magazine (Subscription and Archive)
Miscellaneous
Company Policy Changes
Information Rights
Statistics & Surveys
Business Register Statistics
DTI Reports
Customer Satisfaction Surveys
Supplying Companies House
International Relations
Our main functions
The main functions of Companies House are to:
incorporate and dissolve limited companies;
examine and store company information delivered under the Companies Act
and related legislation; and
make this information available to the public.
The Registrar of Companies
The Registrar of Companies for England and Wales, and Chief Executive of
Companies House is Claire Clancy. Her office is based at Companies House
in Cardiff.
The Registrar of Companies for Scotland is Dorothy Blair and her office is
based in Edinburgh.
There is also an Information Centre in London.
Click here for details on where to Find us and Who to Contact
History
The United Kingdom has enjoyed a system of company registration since
1844. Today, company registration matters are dealt with in law, by the
Companies Act 1985 and the updating legislation contained in the Companies
Act 1989.
All limited companies in the UK are registered at Companies House, an
Executive Agency of the Department of Trade and Industry. There are more
than 2 million limited companies registered in Great Britain, and more
than 300,000 new companies are incorporated each year.
Press Notice Archive
<http://www.companies-house.gov.uk/pressDesk/pressArchive.shtml>
02 December 2003 - Company Re-registration
November 2003 - Companies House website re-launched
5 November 2003 - The perils of the name game
31 October 2003 - Postal disputes: filing documents at Companies House
16 October 2003 - Companies House visits Stoke-on-Trent
March 2003 - Registering a greener future
December 2002 - Companies House to close three Information Centres
June 2002 - Companies House visits Bolton
June 2002 - Companies House visits Preston
May 2002 - Companies House visits Maldon
"Company accounts rules are Convention compliant" - Judgement 18 December
2002
WebFiling Service
<http://www.companies-house.gov.uk/infoAndGuide/faq/webFiling.shtml>
WebFiling FAQ's - (PDF - 138KB)
WebFiling User Guide - (PDF - 1.68MB)
WebFiling Demo
WebFiling Feedback
WebFiling Case Studies
File Accounts via WebFiling
You can now submit Dormant Company Accounts (DCA Format) and Audit Exempt
Abbreviated Accounts via the WebFiling service. These two accounts types
alone make up the majority of accounts filed at Companies House.
Tools to Help You - Find Information on a Company
<http://www.companies-house.gov.uk/toolsToHelp/findCompanyInfo.shtml>
WebCHeck
The WebCHeck service offers a free of charge searchable Company Names and
Address Index which enables you to search for information on more than 2
million companies. You can carry out a search on a company by using either
its name or its unique company registration number. In addition to the
free company details, you can also use WebCHeck to purchase a companys
latest accounts and annual returns as well as a selection of company
reports, all online. Payment is made by credit card and all products are
delivered electronically to a unique, secure download area.
Companies House Direct
Companies House Direct is our premier search tool for accessing and
downloading company information directly from your own PC. Over 240
million images of company documents are available including company
accounts, as well as a wide range of database information. Companies House
Direct is a subscription service, so you will need to open an account with
us. Opening an account is now free; thereafter a monthly subscription fee
of 5.00 is charged as part of your monthly invoice, which would also
include any documents or products that you may have purchased.
Monitor
You can keep an eye on your competitors or even your own company and
monitor which documents have been filed into Companies House, using the
Monitor service within Companies House Direct. Just register your email
address, and details of the companies and documents you are interested in.
As soon as the documents are received, the system will recognise your
interest and send you an email notification. You can then decide whether
you wish to order the document image. The choice is yours.
DVD ROM Directory
The DVD ROM Directory contains basic company details on over 2 million
live companies registered in England, Scotland and Wales along with
companies that have become dissolved in the last month. The DVD has a
built in search facility that allows up to 6 combinations of searches to
be made. The search options are company name, company number, registered
office address lines, postcode, date of incorporation or range of dates,
SIC(03) Codes or description, company type, company status or accounts
type.
The directory is produced monthly and you can purchase a single copy for
30 or a years subscription for 300.
----------------------------------------
Read more at the URL immediately above.
Sincerely,
David Dillard
Temple University
(215) 204 - 4584
[EMAIL PROTECTED]
Net-Gold
<http://groups.yahoo.com/group/net-gold>
<http://listserv.temple.edu/archives/net-gold.html>
General Internet & Print Resources
<http://library.temple.edu/articles/subject_guides/general.jsp>
<http://www.learningis4everyone.org/>
<http://www.edu-cyberpg.com/ringleaders/davidd.html>
Digital Divide Network
<http://www.digitaldivide.net/profile/jwne>
Educator-Gold
<http://groups.yahoo.com/group/Educator-Gold/>
Messages in this topic (1)
________________________________________________________________________
________________________________________________________________________
3. WEB SITE DESIGN AND PROMOTION: USABILITY: Research Based Web Design
Posted by: "David P. Dillard" [EMAIL PROTECTED] jwneastro
Date: Thu Jan 25, 2007 4:28 am ((PST))
WEB SITE DESIGN AND PROMOTION: USABILITY:
Research Based Web Design and Usability Guidelines
U.S. Department of Health and Human Services
and
The U.S. General Services Administration
Research Based Web Design and Usability Guidelines
<http://usability.gov/pdfs/guidelines.html>
View and Print Entire Guidelines Book (2006 ed.)
(292 pages, 161 MB)
http://usability.gov/pdfs/guidelines_book.pdf
View and Print Guidelines Book (2006 ed.) by Section
Introduction and Background
Guidelines by Chapter
Sources/Bibliographies
Glossary, Indices, and Appendices
What's changed in the Guidelines 2006 edition?
Features
Guidelines Sorting Tool:
Sort Guidelines by Title, Importance, Strength of Evidence, and Other
Options
Introduction and Background (2006 ed.)
Beginning of Book and Forewords (7 pages, 696 KB)
Michael O. Leavitt, Secretary of Health and Human Services
Ben Shneiderman, University of Maryland
Introduction (2 pages, 504 KB)
Background and Methodology (3 pages, 528 KB)
Includes detailed Strength of Evidence scale
How to Use the Guidelines (3 pages, 524 KB)
Includes important considerations for using the Guidelines
Contributors (2 pages, 496 KB)
Guidelines by Chapter (2006 ed.)
Chapter 1 Design Process and Evaluation (8 pages, 1.8 MB)
Chapter 2 Optimizing the User Experience (13 pages, 8.9 MB)
Chapter 3 Accessibility (7 pages, 2.4 MB)
Chapter 4 Hardware and Software (5 pages, 2.8 MB)
Chapter 5 The Homepage(10 pages, 11.8 MB)
Chapter 6 Page Layout (14 pages, 20.4 MB)
Chapter 7 Navigation (13 pages, 12.8 MB)
Chapter 8 Scrolling and Paging (5 pages, 4.4 MB)
Chapter 9 Headings, Titles, and Labels (9 pages, 7.7 MB)
Chapter 10 Links (15 pages, 16.7 MB)
Chapter 11 Text Appearance(11 pages, 11 MB)
Chapter 12 Lists (9 pages, 6.4 MB)
Chapter 13 ScreenBased Controls (Widgets) (22 pages, 14.7 MB)
Chapter 14 Graphics, Images, and Multimedia (16 pages, 16.5 MB)
Chapter 15 Writing Web Content (11 pages, 10.8 MB)
Chapter 16 Content Organization(10 pages, 9.8 MB)
Chapter 17 Search (9 pages, 8.9 MB)
Chapter 18 Usability Testing (10 pages, 1,020 KB)
Sources/Bibliographies (2006 ed.)
Complete Bibliography (29 pages, 2.8 MB)
Glossary, Indices, and Appendices (2006 ed.)
Glossary (7 pages, 904 KB)
Content Index (14 pages, 3 MB)
Author Index (10 pages, 2.2 MB)
Appendices 10 pages, 1.2 MB)
Guidelines ranked by Relative Importance and Strength of Evidence
Introduction
<http://usability.gov/pdfs/introduction.pdf>
The Research-Based Web Design & Usability Guidelines (Guidelines) were
developed by the U.S. Department of Health and Human Services (HHS), in
partnership with the U.S. General Services Administration. This new
edition of the Guidelines updates the original set of 187 guidelines, and
adds 22 new ones. Many of the guidelines were edited, and numerous new
references have been added. There are now 209 guidelines.
The Guidelines were developed to assist those involved in the creation of
Web sites to base their decisions on the most current and best available
evidence. The Guidelines are particularly relevant to the design of
information-oriented sites, but can be applied across the wide spectrum of
Web sites.
Who Are the Guidelines for?
The primary audiences for the Guidelines are Web site managers, designers,
and others involved in the creation or maintenance of Web sites. A
secondary audience is researchers who investigate Web design issues. This
resource will help researchers determine what research has been conducted,
and where little or no research exists.
Why Were the Guidelines Created?
HHS created this set of guidelines for several reasons:
1) To create better and more usable health and human service Web sites.
HHS is mandated to provide clear information in an efficient and effective
manner to patients, health professionals, researchers, and the public.
Translating the latest Web design research into a practical, easy-to-use
format is essential to the effective design of HHS numerous Web sites. The
approach taken to produce the Guidelines is consistent with HHS overall
health information dissemination model that involves rapidly collecting,
organizing, and distributing information in a usable format to those who
need it.
2) To provide quantified, peer-reviewed Web site design guidelines. This
resource does not exist anywhere else. Most Web design guidelines are
lacking key information needed to be effective.
For example, many guideline sets:
Are based on the personal opinions of a few experts;
Do not provide references to support them;
Do not provide any indication as to whether a particular guideline
represents a consensus of researchers, or if it has been derived from a
one-time, non-replicated study; and
Do not give any information about the relative importance of individual
guidelines.
How to Use the Guidelines
<http://usability.gov/pdfs/how_to_use.pdf>
Successful use of the Guidelines depends on how they are disseminated and
used within an organization. Simply providing the Guidelines to designers
and managers may not be enough to spur the adoption and use of these
guidelines.
The Guidelines offer benefits to four key audiences:
Designers
The Guidelines provide a clear sense of the range of issues that
designersespecially those new to the fieldneed to consider when planning
and designing a Web site. Applying the Guidelines will help to reduce the
negative impacts of opinion-driven design, and referring to evidence-based
guidance can reduce the clashes resulting from differences of opinion
between design team members.
Usability Specialists
The Guidelines will help usability specialists evaluate the designs of Web
sites. For example, usability specialists can use the Guidelines as a
checklist to aid them during their review of Web sites. They also can
create customized checklists that focus on the Relative Importance and
Strength of Evidence scales associated with each guideline. For example, a
usability specialist can create a checklist that only focuses on the top
25 most important issues related to the success of a Web site.
Managers
The Guidelines will provide managers with a good overview and deep
understanding of the wide range of usability and Web design issues that
designers may encounter when creating Web sites.The Guidelines also
provide managers with a standard of usability for their designers.
Managers can request that designers follow relevant portions of the
Guidelines and can use the Guidelines to set priorities. For example,
during timeframes that require rapid design, managers can identify
guidelines deemed most important to the success of a Web siteas defined by
the Relative Importance score associated with each guidelineand require
designers to focus on implementing those selected guidelines.
Researchers
Researchers involved in evaluating Web design and Web process issues can
use this set of Guidelines to determine where new research is needed.
Researchers can use the sources of evidence provided for each guideline to
assess the research that has been conducted, and to determine the need for
additional research to increase the validity of the previous findings, or
to challenge these findings. Perhaps more importantly, researchers also
can use the Guidelines and their sources to formulate new and important
research questions.
Options for Implementing the Guidelines
There are a variety of ways to use the Guidelines in Web site development
efforts. Users can read the book from beginning to end to become familiar
with all of the guidelines. The book also can be used as a reference to
answer specific Web site design questions. The Guidelines can be
customized to fit most organizations needs. The customization process can
be approached in several ways:
Encourage key stakeholders and/or decision makers to review the full set
of guidelines and identify key guidelines that meet their Web design
needs. For example, an organization may be developing portal Web sites
that focus exclusively on linking to other Web sites (as opposed to
linking to content within its own Web site). Therefore, it may focus more
on selecting guidelines from the designing links and navigation chapters
and less from the content-related chapters.
Selected guidelines can be merged with existing standards and guidelines
currently used within an organization. This may reduce the number of
documents or online tools that designers must reference, and improve the
adoption and use of existing standards and the Guidelines.
The Relative Importance and Strength of Evidence scales can be used to
prioritize which guidelines to implement. For example, on page 205 of this
book, the guidelines are listed in order of relative importance. Using
this list, designers can focus on implementing the 25 or 50 most important
guidelines. In turn, the Strength of Evidence ratings on page 210 can be
used to determine the guidelines in which a designer can place the
greatest confidence. Conversely, the guidelines with the lowest Strength
of Evidence ratings could indicate where more time should be devoted
during usability testing. To help readers customize these guidelines to
meet their organizations needs, an electronic copy of the Guidelines is
posted at
<http://usability.gov/>
Finally, Ben Shneiderman, Ph.D., suggests four ways to enhance the
application of the Guidelines: education, enforcement, exemption, and
enhancement. Please read his foreword to consider other ways to
successfully implement the Guidelines.
Considerations Before Using the Guidelines
The guidelines are intended to improve the design and usability of
information-based Web sites, but also can be applied across the wide
spectrum of Web sites. When using the guidelines, it is helpful to
remember that:
Within each chapter of this book, the guidelines are ordered according to
their Relative Importance ratings. That is, the most important guidelines
are toward the beginning of a chapter and the less important ones are
toward the end.
Readers may have a tendency to think that guidelines with one or two
bullets on the Relative Importance scale are not important. However, it is
crucial to note that all guidelines in this book were rated as at least
somewhat important by the review team, otherwise they would not have been
selected for inclusion in the book. Therefore, a guideline with one or two
bullets is still important, just relatively less so than a guideline with
four or five bullets.
The guidelines may not be applicable to all audiences and contexts. For
example, they may not apply to Web sites used by audiences with low
literacy skills that have special terminology and layout needs. In
general, these guidelines apply to English language Web sites designed for
adults who are between 18 and 75 years of age.
The guidelines may not adequately consider the experience of the
designer. For example, a designer may have specialized knowledge about
designing for a particular audience or context. These guidelines are
adaptable and are not fixed rules.
The guidelines may not reflect all evidence from all disciplines related
to Web design and usability. Considerable effort has been made to include
research from a variety of fields including human factors, cognitive
psychology, computer science, usability, and technical communication.
However, other disciplines may have valuable research that is not
reflected in the guidelines.
Some Strength of Evidence ratings are low because there is a lack of
research for that particular issue. The Strength of Evidence scale used to
rate each guideline was designed to put a high value on research-based
evidence, but also to acknowledge experience-based evidence including
expert opinions. Low Strength of Evidence ratings should encourage the
research of issues that are not currently investigated.
Sincerely,
David Dillard
Temple University
(215) 204 - 4584
[EMAIL PROTECTED]
Net-Gold
<http://groups.yahoo.com/group/net-gold>
<http://listserv.temple.edu/archives/net-gold.html>
General Internet & Print Resources
<http://library.temple.edu/articles/subject_guides/general.jsp>
<http://www.learningis4everyone.org/>
<http://www.edu-cyberpg.com/ringleaders/davidd.html>
Digital Divide Network
<http://www.digitaldivide.net/profile/jwne>
Educator-Gold
<http://groups.yahoo.com/group/Educator-Gold/>
Messages in this topic (1)
________________________________________________________________________
________________________________________________________________________
This e-mail service is voluntarily managed and moderated by
George Lessard http://mediamentor.ca
Public, keyword searchable archives @
http://groups.yahoo.com/group/mediamentor
RSS feed for MediaMentor list:
http://rss.groups.yahoo.com/group/mediamentor/rss
FEEDBACK:
[EMAIL PROTECTED]
POST: If subscribed, post to the list @ [email protected]
No attachments...... less viruses.... text only please....
No HTML and no RTF from your subscription's e-mail address only.
UNSUBSCRIBE:
[EMAIL PROTECTED]
Change your subscription to daily digest mode
by sending a blank message to
[EMAIL PROTECTED]
Change your subscription to individual emails:
by sending a blank message to
[EMAIL PROTECTED]
Put your email message delivery on hold for your vacation:
by sending a blank message to
[EMAIL PROTECTED]
(c)info
http://members.tripod.com/~media002/disclaimer.htm
Due to the nature of email & the WWW,
check ALL sources.
Members who post to this list retain their copyright but grant a non-exclusive
license to others to forward any message posted here. They also grant the list
owner permission to maintain an archive or approve the archiving of list
messages.
Other use of e-mail to this list requires the permission of individual writers..
Also.... Mr. Yahoo! says.....
------------------------------------------------------------------------
Yahoo! Groups Links
<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/mediamentor/
<*> Your email settings:
Digest Email | Traditional
<*> To change settings online go to:
http://groups.yahoo.com/group/mediamentor/join
(Yahoo! ID required)
<*> To change settings via email:
mailto:[EMAIL PROTECTED]
mailto:[EMAIL PROTECTED]
<*> To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/
------------------------------------------------------------------------
